Pfizer CD70 CAR Chimeric Antigen Receptor Patent Application EP3746483A1
Summary
The European Patent Office published Pfizer Inc.'s patent application EP3746483A1 for chimeric antigen receptors targeting CD70. The application (A1 publication with European search report) covers compositions and methods for CD70-targeting CARs with 11 named inventors including Srivatsa Srinivasan and Barbra Johnson Sasu. The application designates all EU member states plus other EPC contracting states.
What changed
EPO published Pfizer's patent application EP3746483A1 for chimeric antigen receptors targeting CD70. The A1 publication with European search report covers C07K 16/28 and A61K 39/00 classified compositions. The application designates 36 EPC contracting states including all EU member states, Switzerland, Norway, and Turkey.
For pharmaceutical companies and biotech firms developing CAR-T or immunotherapy products, this patent publication establishes a priority date of August 9, 2019 for Pfizer's CD70 CAR technology. Competitors developing similar CD70-targeting therapies should conduct freedom-to-operate analyses and monitor the prosecution of this application for claims that may affect their programs.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHIMERIC ANTIGEN RECEPTORS TARGETING CD70
Publication EP3746483A1 Kind: A1 Apr 08, 2026
Applicants
Pfizer Inc.
Inventors
SRIVATSA SRINIVASAN, Surabhi, NAGARAJAN, Niranjana Aditi, PANOWSKI, Siler, PARK, Yoon, SAI, Tao, SASU, Barbra Johnson, VAN BLARCOM, Thomas John, DUSSEAUX, Mathilde Brunnhilde, GALETTO, Roman Ariel
IPC Classifications
C07K 16/28 20060101AFI20190809BHEP A61K 39/00 20060101ALI20190809BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.